Acadia Pharmaceuticals, Inc. (ACAD) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $20.59 -0.82%
EPS Growth %: -52.4%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
OPY, BNCC, ZVOI, More
EPS Growth %: -52.4%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) reported Q2 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $460 thousand versus the consensus estimate of $480 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
- Gates Industrial Corporation plc (GTES) Tops Q3 EPS by 4c ; Offers Guidance
- Lear Corp. (LEA) Tops Q3 EPS by 39c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
